Skip to content
10-Q

Quarterly Report

iTeos Therapeutics, Inc.

0000950170-25-059357

← back to feed
Filed
Apr 28, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 22, 2025 38.27M sh
Shares Diluted Q1 2025 · Mar 31, 2025 43.24M sh
Shares Diluted Q1 2025 · Mar 31, 2024 35.84M sh
Capex Q1 2025 · Mar 31, 2025 $101K
Capex Q1 2025 · Mar 31, 2024 $945K
Operating Cash Flow Q1 2025 · Mar 31, 2025 −$33.76M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$32.4M
Short Term Investments Q1 2025 · Mar 31, 2025 $363.83M
Short Term Investments Q1 2025 · Dec 31, 2024 $352.52M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $156.54M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $142.13M
Stockholders Equity Q1 2025 · Mar 31, 2025 $563.42M
Stockholders Equity Q1 2025 · Dec 31, 2024 $590.29M
Stockholders Equity Q1 2025 · Mar 31, 2024 $541.2M
Stockholders Equity Q1 2025 · Dec 31, 2023 $575.23M
Current Liabilities Q1 2025 · Mar 31, 2025 $38M
Current Liabilities Q1 2025 · Dec 31, 2024 $40.36M
Total Liabilities Q1 2025 · Mar 31, 2025 $95.45M
Total Liabilities Q1 2025 · Dec 31, 2024 $96.68M
Current Assets Q1 2025 · Mar 31, 2025 $537.05M
Current Assets Q1 2025 · Dec 31, 2024 $509.54M
Total Assets Q1 2025 · Mar 31, 2025 $658.87M
Total Assets Q1 2025 · Dec 31, 2024 $686.98M
Eps Diluted Q1 2025 · Mar 31, 2025 −$0.80
Eps Diluted Q1 2025 · Mar 31, 2024 −$1.07
Eps Basic Q1 2025 · Mar 31, 2025 −$0.80
Eps Basic Q1 2025 · Mar 31, 2024 −$1.07
Sga Expense Q1 2025 · Mar 31, 2025 $10.98M
Sga Expense Q1 2025 · Mar 31, 2024 $12.7M
Rd Expense Q1 2025 · Mar 31, 2025 $29.04M
Rd Expense Q1 2025 · Mar 31, 2024 $34.53M
Net Income Q1 2025 · Mar 31, 2025 −$34.61M
Net Income Q1 2025 · Mar 31, 2024 −$38.22M
Operating Income Q1 2025 · Mar 31, 2025 −$40.02M
Operating Income Q1 2025 · Mar 31, 2024 −$47.23M